GlaxoSmithKline to ax 850 R&D positions

GlaxoSmithKline (GSK) will eliminate 850 research and development (R&D) positions company-wide, including an undisclosed number in Research Triangle Park, N.C.

The plans announced Wednesday are part of a continuing effort, which began in October 2007 to save $1.4 billion a year over the next three years, according to News & Observer.

An undetermined number of the positions the company expects to cut currently are unfilled, the company said. The London-based GSK has more than 15,000 R&D staffers globally, including 2,500 in Research Triangle Park—one of the company’s two U.S. headquarters.
The majority of the job cuts involve scientists, but administrative staff also will be affected, according to G&K.

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.